Analyst Price Targets — CABA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 21, 2024 12:41 pm | Ben Burnett | Stifel Nicolaus | $32.00 | $17.54 | StreetInsider | Cabaletta Bio Inc. (CABA) PT Raised to $32 at Stifel |
| January 3, 2023 9:04 am | — | Wells Fargo | $14.00 | $9.30 | Benzinga | Wells Fargo Maintains Overweight on Cabaletta Bio, Raises Price Target to $14 |
| August 30, 2022 4:59 am | Michael Ulz | Morgan Stanley | $3.00 | $1.26 | TheFly | Cabaletta Bio downgraded to Equal Weight from Overweight at Morgan Stanley |
Latest News for CABA
PHILADELPHIA, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced its participation in the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference: Meetings with investors on…
Registrational RESET-Myositis ® clinical data on track to be reported in mid-2027 to support 2H27 BLA submission for rese-cel
Cabaletta Bio (CABA) offers a de-risked, breadth-first CAR-T platform for autoimmune diseases, with strong EULAR 2026 data and a compelling $2.90/share entry point. CABA's rese-cel is advancing across five indications, with pivotal myositis and systemic sclerosis trials, clean safety profile, and automated manufacturing via Cellares. Recent $150M raise with participation from Eli Lilly and top biotech funds…
Cabaletta Bio, Inc. (CABA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
83% of dermatomyositis patients in the Phase 1/2 RESET-Myositis study would have met the registrational primary endpoint; all these patients maintained their response off immunomodulators through latest follow-up, as long as 1.5 years
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CABA.
U.S. House Trading
No House trades found for CABA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.